Data-driven health care: The only response to exploding Life Sciences demand

Life Sciences is far behind other regulated industries in adopting transformative technology.

- Rand Corporation, Multiple Chronic Conditions in the United States, 2017.
- Pharmaceutical Research and Manufacturers of America, Rare Disease by the Numbers, 2018.
- Deloitte, Embracing the future of work to unlock R&D productivity.

Challenges

- The number of individuals over 85 will TRIPLE between 2015 and 2050.
- Annual expenditure has increased to $10,739 per person, compared to $146 in 1960.
- 50% of the population has a chronic disease.
- 12% have 5+.
- 55% of rare diseases do not have approved medicine.
- 95% of rare diseases do not have approved medicine.
- R&D returns are the lowest in 9 years.
- Approval rates for drugs entering clinical development at less than 12%.

Capitalize on the wealth of data

- Capture and connect data
- Manage risk and ensure governance
- Overcome lengthy development cycles
- Offer context at decision points
- Gain the Information Advantage
- Integrate disparate applications and systems

Big data strategies can inform decision-making and generate up to $100 billion annually across the U.S. healthcare system.

Serve managed data and governance practices to meet FDA and HIPAA requirements.

Drive engagement across customers, partners, stakeholders, and employees.

Leverage interoperable data platforms

Put data to work with OpenText Life Sciences solutions

Talk to an OpenText Life Sciences expert today!